NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more
NextCure Inc (NXTC) - Net Assets
Latest net assets as of September 2025: $23.65 Million USD
Based on the latest financial reports, NextCure Inc (NXTC) has net assets worth $23.65 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.61 Million) and total liabilities ($15.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $23.65 Million |
| % of Total Assets | 59.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | -77.71% |
| 10-Year Change | N/A |
| Growth Volatility | 11.4 |
NextCure Inc - Net Assets Trend (2017–2024)
This chart illustrates how NextCure Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NextCure Inc (2017–2024)
The table below shows the annual net assets of NextCure Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $65.47 Million | -42.78% |
| 2023-12-31 | $114.42 Million | -31.70% |
| 2022-12-31 | $167.53 Million | -28.22% |
| 2021-12-31 | $233.39 Million | -20.54% |
| 2020-12-31 | $293.72 Million | -8.64% |
| 2019-12-31 | $321.48 Million | +784.82% |
| 2018-12-31 | $-46.94 Million | -92.30% |
| 2017-12-31 | $-24.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NextCure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35563800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.04% |
| Other Comprehensive Income | $4.00K | 0.01% |
| Other Components | $445.58 Million | 680.56% |
| Total Equity | $65.47 Million | 100.00% |
NextCure Inc Competitors by Market Cap
The table below lists competitors of NextCure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laboratorios Richmond SACIF
BA:RICH
|
$24.99 Million |
|
NEORIGIN Co. Ltd
KQ:094860
|
$25.00 Million |
|
H-FARM SPA
F:5JQ
|
$25.01 Million |
|
Maniker
KO:027740
|
$25.01 Million |
|
Kora Saude Participacoes SA
SA:KRSA3
|
$24.99 Million |
|
Edisun Power Europe AG
SW:ESUN
|
$24.98 Million |
|
Dorel Industries Inc
PINK:DIIBF
|
$24.98 Million |
|
POZNANSKA K.BUD.P. A ZY1
F:20W
|
$24.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NextCure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 114,421,000 to 65,472,000, a change of -48,949,000 (-42.8%).
- Net loss of 55,654,000 reduced equity.
- New share issuances of 39,000 increased equity.
- Other comprehensive income increased equity by 226,000.
- Other factors increased equity by 6,440,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.65 Million | -85.0% |
| Share Issuances | $39.00K | +0.06% |
| Other Comprehensive Income | $226.00K | +0.35% |
| Other Changes | $6.44 Million | +9.84% |
| Total Change | $- | -42.78% |
Book Value vs Market Value Analysis
This analysis compares NextCure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-12.90 | $12.32 | x |
| 2018-12-31 | $-24.80 | $12.32 | x |
| 2019-12-31 | $245.79 | $12.32 | x |
| 2020-12-31 | $128.02 | $12.32 | x |
| 2021-12-31 | $101.41 | $12.32 | x |
| 2022-12-31 | $72.46 | $12.32 | x |
| 2023-12-31 | $49.33 | $12.32 | x |
| 2024-12-31 | $28.09 | $12.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NextCure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -85.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-85.00%) is below the historical average (-29.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.03 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.10 Million |
| 2019 | -10.49% | -531.54% | 0.02x | 1.11x | $-65.89 Million |
| 2020 | -11.30% | -148.32% | 0.07x | 1.04x | $-62.56 Million |
| 2021 | -29.73% | 0.00% | 0.00x | 1.04x | $-92.73 Million |
| 2022 | -41.45% | 0.00% | 0.00x | 1.10x | $-86.19 Million |
| 2023 | -54.82% | 0.00% | 0.00x | 1.12x | $-74.17 Million |
| 2024 | -85.00% | 0.00% | 0.00x | 1.24x | $-62.20 Million |
Industry Comparison
This section compares NextCure Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NextCure Inc (NXTC) | $23.65 Million | 0.00% | 0.68x | $24.99 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |